460 likes | 875 Views
Herpesviridae - Objectives. To review the members of the Herpesviridae familyTo understand the concepts of primary infection, latent infection and reactivation diseaseTo recognize the common clinical syndromes associated with each virus and the principles of management. . Herpesviridae Family. do
E N D
3. Herpesviridae Family double stranded DNA viruses with envelope
ubiquitous, world-wide distribution
8 human herpesviruses recognized; species specific
Latency - once infected, always infected
- site varies with virus type:
- HSV 1 & 2, VZV - sensory nerve ganglia
- CMV, EBV, HHV6, HHV7 lymphocytes
Replication occurs in the nucleus of infected cell
Viral DNA remains episomal (i.e. not integrated into host cell DNA)
5. Transmission & Seroepidemiology of Herpesviridae
6. Herpesviridae Transmission:
do not survive for prolonged periods in the environment
requires inoculation of fresh virus-containing body fluid of infected person into susceptible tissue of uninfected person
may be transmitted during primary or reactivation infections; often the person shedding virus is asymptomatic
11. Epidemiology of HSV Infections Only 10-15% of HSV-2 primary infections are symptomatic
4 out of every 5 people with genital herpes have not been diagnosed; three out of five people have symptoms that are unrecognized as genital herpes
Recurrent disease can be either symptomatic or asymptomatic
12. Primary herpes, male
13. Herpes, female
14. Herpes cervicitis
19. Recurrences of Genital HSV HSV-2 versus HSV-1 genital herpes rates
Reactivates 49 days versus 310 days after primary
4.5 recurrences per year versus <1
HSV-2 recurrence rates vary widely across people:
26% women and 8% of men have none in first year
14% women and 26% men: >10 recurrences
Recurrence rates trend down (frequency and severity) over the long term
HSV-2 shedding: 5-32% of days (40% subclinical)
20. HSV Complications CNS infections
Perinatal/Congenital
21. Herpes Simplex Virus: CNS Infections Encephalitis:
temporal lobes are the principle target; hemorrhagic necrosis
all ages, all seasons, both sexes
sudden onset or after flu-like prodrome
may be no signs of HSV elsewhere
22. Herpes Simplex Encephalitis
23. Herpes Simplex Virus: CNS Infections Encephalitis:
MRI may detect earlier changes than CT
untreated, rapid deterioration over few days with 60-80% mortality; 90% of survivors have significant neurological sequelae
acyclovir treatment reduces mortality by 50%
25. HSV Congenital/Perinatal Intrauterine infection: rare; follows 10 infection
Perinatal infection:
75% are due to HSV 2; acquired during delivery
many women unaware they are infected; 60 - 80% have no signs or symptoms of genital herpes at time of labour (asymptomatic shedders)
HSV-1 acquired from maternal genital, oral or breast lesions, paternal or other family member, or nosocomial infection from other infected babies
26. HSV Congenital/Perinatal Perinatal Infections:
pregnancy is associated with state of immuno-suppression:?? shedding, ??reactivation, ?recurrences
subclinical infection in neonates is uncommon
not all infants of infected mothers will become infected; depends on 10 (30 50% risk) vs recurrent disease (1 3% risk)
27. HSV Congenital/Perinatal Clinical manifestations of perinatal infection:
disseminated CNS disease (49%)
liver, lungs, eyes, CNS
80 - 85% mortality
localized to CNS, skin, eyes, oral cavity (50%)
10 - 40% mortality
asymptomatic infection (1%)
28. HSV Congenital/Perinatal Treatment:
Mother - acyclovir relatively contraindicated during pregnancy
Neonate - acyclovir if mother has active lesions or prolonged membrane rupture
Prevention:
maternal history, surveillance
if active lesions at time of delivery then C-section indicated
29. Herpes Simplex Virus - Diagnosis History and physical examination
Vesicle fluid: culture, EM, immunofluorescence, molecular (e.g. PCR)
Serology
difficult to distinguish HSV-1 and HSV-2; no reliable IgM test
seroprevalence
cannot distinguish 1 infection from recurrent disease
? Value of type-specific serology
30. Immunoglobulin Response in HSV Infection
31. HSV Serology Patients with Recurrent HSV Infection
65% only IgG
35% both IgG and IgM Patients with Primary Infection
18% -30% with both IgG and IgM antibodies
32. HSV Type-specific Serology:Clinical Role?
33. Why do we need to know who has HSV 2? A)To stop the epidemic spread of genital herpes. HSV is quickly and silently spreading at varying rates across Canada and not just in the high risk populations
B)To permit high risk groups to be able to protect themselves better. HSV has been shown to increase the chance of acquiring HIV by two to three fold and accelerate the rate of HIV disease progression
C)To identify women at risk of acquiring HSV in pregnancy endangering the baby. HSV is potentially fatal in infants if the mother is shedding virus at the time of delivery.
D)To provide counseling HSV-2 infected patients can expect several outbreaks per year and are more likely to benefit from suppression therapy than HSV-1 patients
E)To determine partner sero-status- 75% of source partners find out about their own infection only when their newly-infected partner is diagnosed
34. When should we test for HSV 2? Symptomatic patients: Use to supplement virus detection tests when:
Lesions are negative or not sampled for virus
Recurring symptoms suggest atypical or undiagnosed herpes
Lesions appear herpetic but may have other etiology
High risk patients but not symptomatic:
Patient has history of symptoms
Patients partner has genital herpes
Patient has a history of other STDs
Patient is at risk of HIV infection
Pregnancy:
To screen for HSV-2 unrecognized infection
To determine risk of acquiring infection
To determine partners status for treatment and counseling
37. HHV-6: Roseola Infantum
38. Common Childhood Infections
41. Cytomegalovirus (CMV) Transmission:
1) Sexual
2) Perinatal / Intrauterine
3) Blood / Blood product transfusion
4) Organ / tissue transplantation
5) Close contact
most infections transmitted asymptomatically
42. Cytomegalovirus (CMV) - Clinical Manifestations acute infection is usually asymptomatic or mild; may present as mono-like illness and / or hepatitis
severe disease in:
AIDS - 25% develop site or life - threatening disease
- >90% infected at autopsy
Transplants - 20 - 60% develop infection
Neonates - CMV isolated in urine of 1:100 infants
44. Cytomegalovirus (CMV) Diagnosis:
Culture - slow growing, may take weeks for virus to grow
Electron microscopy - morphology of herpes viruses
Immunofluoresence techniques
Serology - IgM for acute infection
- IgG for past infection
PCR, DNA hybridization
45. Cytomegalovirus (CMV) Treatment:
Immunocompetent patients:
None
Immunocompromised patients:
Ganciclovir
Foscarnet
Prevention:
No vaccine